| Title |
Six-Month Response to Delamanid Treatment in MDR TB Patients - Volume 23, Number 10—October 2017 - Emerging Infectious Diseases journal - CDC
|
|---|---|
| Published in |
Emerging Infectious Diseases, October 2017
|
| DOI | 10.3201/eid2310.170468 |
| Pubmed ID | |
| Authors |
Cathy Hewison, Gabriella Ferlazzo, Zaza Avaliani, Armen Hayrapetyan, Sylvie Jonckheere, Zarema Khaidarkhanova, Erika Mohr, Animesh Sinha, Alena Skrahina, Debrah Vambe, Irina Vasilyeva, Nathalie Lachenal, Francis Varaine |
| Abstract |
Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months. |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 33% |
| Switzerland | 1 | 8% |
| Kenya | 1 | 8% |
| Saudi Arabia | 1 | 8% |
| Unknown | 5 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 82 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 13% |
| Student > Master | 11 | 13% |
| Researcher | 10 | 12% |
| Student > Bachelor | 9 | 11% |
| Student > Ph. D. Student | 4 | 5% |
| Other | 13 | 16% |
| Unknown | 24 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 33% |
| Immunology and Microbiology | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 13 | 16% |
| Unknown | 26 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2017.
All research outputs
#2,417,792
of 25,382,440 outputs
Outputs from Emerging Infectious Diseases
#2,536
of 9,718 outputs
Outputs of similar age
#45,675
of 335,962 outputs
Outputs of similar age from Emerging Infectious Diseases
#46
of 153 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,718 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,962 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.